Director/PDMR Shareholding
HikmaPharmaceuticals PLC
(the “Company”)
LONDON, 22 September 2026: HikmaPharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the below listed Persons Discharging Managerial Responsibilities(“PDMRs”) of the Company acquired OrdinaryShares in the Company, which were purchased under a dividend reinvestment plan("DRIP").
This notificationis made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as itforms part of domestic law by virtue of the European Union (Withdrawal) Act2018 ("MAR"). The information set out below is provided in accordance with therequirements of Article 19(3) of MAR.
Notificationand public disclosure of transactions by Persons Discharging Managerial Responsibilities
SusanRingdal
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Susan Ringdal | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Acquisition of Ordinary Shares through participation in a DRIP. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
£15.97 | 1,684 | ||
d) | Aggregated information | Price(s): £15.97 Volume(s): 1,684 Total: £26,896.23 | |
e) | Date of the transaction | 21 September 2026 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Julie Hill
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Julie Hill | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Acquisition of Ordinary Shares through participation in a DRIP. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
£15.97 | 218 | ||
d) | Aggregated information | Price(s): £15.97 Volume(s): 218 Total: £3,481.82 | |
e) | Date of the transaction | 21 September 2026 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Sam Park
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Sam Park | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Acquisition of Ordinary Shares through participation in a DRIP. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
£15.97 | 207 | ||
d) | Aggregated information | Price(s): £15.97 Volume(s): 207 Total: £3,306.13 | |
e) | Date of the transaction | 21 September 2026 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Helen Middlemist
Group Company Secretary
+44 (0) 20 7399 2760